Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Respiration Physiology|November 1, 1986
Effects of altering dead space volume on respiration and air sac gases in geeseM R Fedde, R E Burger, J Geiser, et al.
British Journal of Cancer|September 1, 1996
High levels of loss at the 17p telomere suggest the close proximity of a tumour suppressorG R White, M Stack, M Santibáñez-Koref, et al.
Lung Cancer (Amsterdam, Netherlands)|June 15, 2014
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)M Joerger, F Baty, M Früh, et al.
Surgical Endoscopy|March 13, 2019
S128: Active post discharge surveillance program as a part of Enhanced Recovery After Surgery protocol decreases emergency department visits and readmissions in colorectal patientsDaniel J Borsuk, Ahmed Al-Khamis, Andrew J Geiser, et al.
The American Surgeon|May 26, 2019
Rectal Cancer Complete Response Outcomes in a Community-Based Hospital Comparable with Large Cancer Centers When Multidisciplinary Approach to Rectal Cancer Is UsedAndrew J Geiser, Ahmed Al-Khamis, Supriya Patel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 5, 2006
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL)D C Betticher, G Martinelli, J A Radford, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2015
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)D Koeberle, D C Betticher, R von Moos, et al.
British Journal of Cancer|April 20, 2006
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II studyD C Betticher, S-F Hsu Schmitz, M Tötsch, et al.
ESMO Open|April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trialsD König, S Schär, D Vuong, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|March 15, 2019
Alternatives for Allergens in the 2018 American Contact Dermatitis Society Core Series: Report by the American Contact Alternatives GroupAndrew Scheman, Sara Hylwa-Deufel, Sharon E Jacob, et al.
Pageof 10